This Article Figures Only Full Text Full Text (PDF) View Related Interview All Versions of this Article: j.jacc.2009.07.008v1 54/19/1778    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Miceli, A. Articles by Caputo, M. Search for Related Content PubMed Articles by Miceli, A. Articles by Caputo, M. Related Collections Related Articles

EXPEDITED PUBLICATION

Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Clinical Outcome in Patients Undergoing Coronary Artery Bypass Grafting

Bristol Heart Institute, University of Bristol, United Kingdom

Manuscript received February 13, 2009; revised manuscript received June 29, 2009, accepted July 8, 2009.

^_* Reprint requests and correspondence: Dr. Massimo Caputo, Bristol Heart Institute, Cardiac Surgery, Level/Upper Maudlin Street, Bristol BS2 8HW, United Kingdom (Email: M.Caputo{at}bristol.ac.uk).

This paper was presented at the 58th Annual Scientific Session of the American College of Cardiology, March 28 to 31, 2009, Orlando, Florida.

Objectives: This study evaluates the effect of pre-operative angiotensin-converting enzyme inhibitor (ACEI) therapy on early clinical outcomes after coronary artery bypass grafting (CABG).

Background: Therapy with ACEIs has been shown to reduce the rate of mortality and prevent cardiovascular events in patients with coronary artery disease. However, their pre-operative use in patients undergoing CABG is still controversial.

Methods: A retrospective, observational, cohort study was undertaken of prospectively collected data on 10,023 consecutive patients undergoing isolated CABG between April 1996 and May 2008. Of these, 3,052 patients receiving pre-operative ACEI were matched to a control group by propensity score analysis.

Results: Overall rate of mortality was 1%. Pre-operative ACEI therapy was associated with a doubling in the risk of death (1.3% vs. 0.7%; odds ratio [OR]: 2.00, 95% confidence interval [CI]: 1.17 to 3.42; p = 0.013). There was also a significant difference between the ACEI and control group in the risk of post-operative renal dysfunction (PRD) (7.1% vs. 5.4%; OR: 1.36, 95% CI: 1.1 to 1.67; p = 0.006), atrial fibrillation (AF) (25% vs. 20%; OR: 1.34, 95% CI: 1.18 to 1.51; p < 0.0001), and increased use of inotropic support (45.9% vs. 41.1%; OR: 1.22, 95% CI: 1.1 to 1.36; p < 0.0001). In a multivariate analysis, pre-operative ACEI treatment was an independent predictor of mortality (p = 0.04), PRD (p = 0.0002), use of inotropic drugs (p < 0.0001), and AF (p < 0.0001).

Conclusions: Pre-operative therapy with ACEI is associated with an increased risk of mortality, use of inotropic support, PRD, and new onset of post-operative AF.

Key Words: angiotensin-converting enzyme inhibitors • coronary artery bypass grafting • outcome

Abbreviations and Acronyms   ACEI = angiotensin-converting enzyme inhibitor   AF = atrial fibrillation   CABG = coronary artery bypass grafting   CI = confidence interval   MI = myocardial infarction   NYHA = New York Heart Association   OR = odds ratio   PRD = post-operative renal dysfunction

Related Articles

Angiotensin-Converting Enzyme Inhibitor Therapy at the Time of Coronary Artery Bypass Surgery: When a Friend Turns Mean-Spirited

David S. Bach
J. Am. Coll. Cardiol. 2009 54: 1785-1786. [Full Text] [PDF]